Financing, Equity Capital Markets
Edgewise Therapeutics
04/25
|
$200.0 Million
Âé¶¹´«Ã½ served as bookrunner for Edgewise Therapeutics on its registered direct offering
Sub-Type
Registered Direct
Sector
Sub-Sector
Biopharma